Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Japanese Subjects with Moderately to Severely Active Ulcerative Colitis
jRCT2080220693Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in autoimmune colitis (3 arms), sponsored by AbbVie Inc.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080220693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220693.